ProMetic Life Sciences Inc. (PLI) 2005年年度报告「TSX」.pdf

1、Straight tothe 2005 Annual RPierre LaurinChairman,President and Chief Executive OfficerThe investments we have made inthe research and development of ourenabling technologies have borne fruitand we are now in the process ofadvancing into the commercializationphase.With the development riskbehind us,

2、our mission is to executeand turn our scientific achievementsinto product sales.2005 Annual ReportMessage to Shareholders1from Pierre LaurinValidating our promisesIn the year past,ProMetic Lifes Sciences Inc.and its subsidiaries(“ProMetic”or the“Company”)have delivered on their scientific milestones

3、.With an impressive performance in Phase I and its mecha-nism of action unraveled,our potential blockbuster drug to treat anemia,PBI-1402,is entering Phase Ib/II clinical trial.Setback and opportunity The commercial implementation of our plasma protein extraction process experi-enced some setback in

4、 2005 with the insolvency of our client and partner Hemosol.However,we are deter-mined not to let this delay the evolution of our technology.The relationship with Hemosol demonstrated thevalue of this process for ProMetic.We showed that this proprietary process performs to the full extent of ourexpe

5、ctations,and results in significant yield advantages over current industry standards.With a global marketfor plasma-derived therapeutics exceeding US$7 billion,this process is well positioned to become a major valuedriver for ProMetic.The endogenous infectivity study for Pathogen Removal and Diagnos

6、tic Technologies Inc.s(PRDT)prion filters was successfully completed,and is now the first to demonstrate the reduction ofTransmissible Spongiform Encephalopathy(TSE)prions from whole blood beyond detectable levels,leadingtowards CE Mark approval and launch in 2006 of the prion reduction filter by ou